Cartesian Therapeutics (RNAC) Competitors

$6.75 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$6.75 0.00 (0.00%)

As of 05/22/2026 04:10 PM Eastern

RNAC vs. AKTS, DSGN, PHAT, SLS, and SANA

Should you buy Cartesian Therapeutics stock or one of its competitors? MarketBeat compares Cartesian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cartesian Therapeutics include Aktis Oncology (AKTS), Design Therapeutics (DSGN), Phathom Pharmaceuticals (PHAT), SELLAS Life Sciences Group (SLS), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

How does Cartesian Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Aktis Oncology has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

In the previous week, Aktis Oncology had 5 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 6 mentions for Aktis Oncology and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.00 beat Aktis Oncology's score of -0.62 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Negative
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aktis Oncology has higher revenue and earnings than Cartesian Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	167.10	N/A	N/A	N/A
Cartesian Therapeutics	$2.80M	70.83	-$130.30M	-$5.90	N/A

Aktis Oncology presently has a consensus price target of $32.00, suggesting a potential upside of 57.33%. Cartesian Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 388.89%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aktis Oncology beats Cartesian Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Design Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Design Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Design Therapeutics	N/A	-33.07%	-31.29%

Design Therapeutics has lower revenue, but higher earnings than Cartesian Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	70.83	-$130.30M	-$5.90	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Design Therapeutics had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Design Therapeutics and 1 mentions for Cartesian Therapeutics. Design Therapeutics' average media sentiment score of 0.44 beat Cartesian Therapeutics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cartesian Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

Cartesian Therapeutics currently has a consensus target price of $33.00, indicating a potential upside of 388.89%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 50.41%. Given Cartesian Therapeutics' higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Design Therapeutics beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Phathom Pharmaceuticals?

Cartesian Therapeutics (NASDAQ:RNAC) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Phathom Pharmaceuticals had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Phathom Pharmaceuticals and 1 mentions for Cartesian Therapeutics. Phathom Pharmaceuticals' average media sentiment score of 0.15 beat Cartesian Therapeutics' score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phathom Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cartesian Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Cartesian Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	70.83	-$130.30M	-$5.90	N/A
Phathom Pharmaceuticals	$175.11M	5.16	-$221.25M	-$2.12	N/A

Cartesian Therapeutics currently has a consensus target price of $33.00, indicating a potential upside of 388.89%. Phathom Pharmaceuticals has a consensus target price of $25.00, indicating a potential upside of 120.65%. Given Cartesian Therapeutics' higher probable upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Phathom Pharmaceuticals has a net margin of -76.77% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Summary

Phathom Pharmaceuticals beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to SELLAS Life Sciences Group?

Cartesian Therapeutics (NASDAQ:RNAC) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Cartesian Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	70.83	-$130.30M	-$5.90	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 1 mentions for Cartesian Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.32 beat Cartesian Therapeutics' score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 1.4% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cartesian Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

Cartesian Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 388.89%. SELLAS Life Sciences Group has a consensus target price of $10.00, suggesting a potential upside of 28.53%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cartesian Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cartesian Therapeutics beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Sana Biotechnology?

Cartesian Therapeutics (NASDAQ:RNAC) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Cartesian Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	70.83	-$130.30M	-$5.90	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Sana Biotechnology has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Sana Biotechnology	N/A	-108.01%	-40.68%

Cartesian Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market.

Cartesian Therapeutics presently has a consensus price target of $33.00, indicating a potential upside of 388.89%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 209.45%. Given Cartesian Therapeutics' higher probable upside, research analysts clearly believe Cartesian Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 1 articles in the media. Cartesian Therapeutics' average media sentiment score of 0.00 equaled Sana Biotechnology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cartesian Therapeutics beats Sana Biotechnology on 7 of the 12 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAC vs. The Competition

Export

Metric	Cartesian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$198.33M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.14	18.74	21.22	25.65
Price / Sales	70.83	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-1.34	7.09	10.37	7.14
Net Income	-$130.30M	$24.45M	$3.57B	$335.98M
7 Day Performance	10.84%	6.38%	6.40%	4.15%
1 Month Performance	N/A	2.43%	3.52%	2.54%
1 Year Performance	-26.31%	62.98%	34.02%	35.05%

Cartesian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAC Cartesian Therapeutics	2.6296 of 5 stars	$6.75 flat	$33.00 +388.9%	-26.3%	$198.33M	$2.80M	N/A	64
AKTS Aktis Oncology	1.7925 of 5 stars	$19.73 +8.0%	$32.00 +62.2%	N/A	$975.68M	$6.50M	N/A	76	Gap Down
DSGN Design Therapeutics	3.3693 of 5 stars	$15.79 +1.2%	$16.50 +4.5%	+187.9%	$974.95M	N/A	N/A	40	Gap Up
PHAT Phathom Pharmaceuticals	2.4741 of 5 stars	$12.53 +2.5%	$25.00 +99.5%	+181.8%	$974.62M	$175.11M	N/A	110
SLS SELLAS Life Sciences Group	1.583 of 5 stars	$5.22 -0.6%	$10.00 +91.6%	+311.6%	$968.80M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. AKTS, DSGN, PHAT, SLS, and SANA

How does Cartesian Therapeutics compare to Aktis Oncology?

Summary

How does Cartesian Therapeutics compare to Design Therapeutics?

Summary

How does Cartesian Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Cartesian Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does Cartesian Therapeutics compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. AKTS, DSGN, PHAT, SLS, and SANA

How does Cartesian Therapeutics compare to Aktis Oncology?

Is AKTS or RNAC more profitable?

Does the media favor AKTS or RNAC?

Which has better valuation and earnings, AKTS or RNAC?

Do analysts recommend AKTS or RNAC?

Do insiders and institutionals have more ownership in AKTS or RNAC?

Summary

How does Cartesian Therapeutics compare to Design Therapeutics?

Do institutionals and insiders believe in RNAC or DSGN?

Is RNAC or DSGN more profitable?

Which has stronger earnings and valuation, RNAC or DSGN?

Does the media refer more to RNAC or DSGN?

Which has more risk & volatility, RNAC or DSGN?

Do analysts recommend RNAC or DSGN?

Summary

How does Cartesian Therapeutics compare to Phathom Pharmaceuticals?

Do insiders & institutionals believe in RNAC or PHAT?

Does the media prefer RNAC or PHAT?

Which has more volatility and risk, RNAC or PHAT?

Which has higher valuation & earnings, RNAC or PHAT?

Do analysts recommend RNAC or PHAT?

Is RNAC or PHAT more profitable?

Summary

How does Cartesian Therapeutics compare to SELLAS Life Sciences Group?

Which has stronger earnings & valuation, RNAC or SLS?

Is RNAC or SLS more profitable?

Does the media prefer RNAC or SLS?

Do insiders and institutionals have more ownership in RNAC or SLS?

Which has more volatility & risk, RNAC or SLS?

Do analysts prefer RNAC or SLS?

Summary

How does Cartesian Therapeutics compare to Sana Biotechnology?

Which has better earnings and valuation, RNAC or SANA?

Is RNAC or SANA more profitable?

Which has more volatility & risk, RNAC or SANA?

Do analysts rate RNAC or SANA?

Does the media prefer RNAC or SANA?

Do institutionals and insiders hold more shares of RNAC or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools